AFPBristol-Myers to Buy Diabetes Maker Amylin for $5.3 BillionBloombergBristol-Myers (BMY) Squibb Co. agreed to pay $5.3 billion to acquire Amylin Pharmaceuticals Inc. (AMLN), a maker of diabetes therapies, as it seeks to replace revenue from its top-selling blood thinner that's facing generic competition.Bristol-Myers to buy Amylin for about $5.3 billionReutersBristol Will Buy Diabetes Drug MakerWall Street JournalBristol-Myers Squibb to buy Amylin for $7 blnAFPForbes -Moneycontrol.com -Los Angeles Timesall 67 news articles »